Talphera (TLPH) Non-Current Deffered Revenue (2010 - 2022)
Talphera's (TLPH) quarterly Non-Current Deffered Revenue came in at $1.0 million in Q4 2022, down 9.99% year-on-year from $1.2 million in Q4 2021, and down 2.63% quarter-over-quarter from $1.1 million in Q3 2022.
Talphera (TLPH) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Talphera's Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $1.0 million for Q4 2022.
- On a quarterly basis, Non-Current Deffered Revenue fell 9.99% year-over-year to $1.0 million in Q4 2022; TTM through Dec 2022 was $1.0 million, a 9.99% decrease from a year earlier, with the FY2022 full-year figure at $1.0 million, down 9.99% from the prior year.
- Non-Current Deffered Revenue fell to $1.0 million in Q4 2022 per TLPH's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $3.4 million in Q1 2018 and bottomed at $1.0 million in Q4 2022.
- The 5-year median for Non-Current Deffered Revenue is $2.8 million (2019), against an average of $2.3 million.
- Across the five-year window, Non-Current Deffered Revenue jumped 1108.61% in 2018 and declined 13.99% in 2022, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $3.1 million in 2018, then fell by 10.01% to $2.8 million in 2019, then fell by 2.79% to $2.8 million in 2020, then tumbled by 58.21% to $1.2 million in 2021, then fell by 9.99% to $1.0 million in 2022.
- Per Business Quant, the three latest TLPH Non-Current Deffered Revenue figures stand at $1.0 million (Q4 2022), $1.1 million (Q3 2022), and $1.1 million (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 1.12 Mn |
| Dec 31, 2021 | 1.15 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Mar 31, 2020 | 2.75 Mn |
| Dec 31, 2019 | 2.83 Mn |
| Sep 30, 2019 | 2.91 Mn |
| Jun 30, 2019 | 2.99 Mn |
| Mar 31, 2019 | 3.07 Mn |
| Dec 31, 2018 | 3.15 Mn |
| Sep 30, 2018 | 3.23 Mn |
| Jun 30, 2018 | 3.31 Mn |
| Mar 31, 2018 | 3.38 Mn |
| Dec 31, 2017 | 3.46 Mn |
| Sep 30, 2017 | 267,000.00 |
| Jun 30, 2017 | 3.64 Mn |
| Mar 31, 2017 | 3.73 Mn |
| Dec 31, 2016 | 43,000.00 |